Latest revision as of 22:55, 27 June 2024

Back to Top

Section editor
	Sanjay R. Mohan, MD, MSCI Vanderbilt University Nashville, TN, USA

8 regimens on this page 9 variants on this page

Are you looking for a regimen, but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!

We have moved How I Treat articles to a dedicated page.

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018 Jan 10;8(1):2. link to original article PubMed

ELN

2011: Barbui et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet PubMed

ESMO

2015: Vannucchi et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed

NCCN

NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Myeloproliferative Neoplasms.

First-line therapy

Anagrelide monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Gisslinger et al. 2013 (ANAHYDRET)	2002-2006	Phase 3 (E-switch-ooc)	Hydroxyurea +/- Aspirin	Non-inferior composite primary endpoint
Gisslinger et al. 2019 (TEAM-ET 2.0)	NR	Phase 3 (C)	Anagrelide; prolonged release	Non-inferior mean platelet count

Anticoagulation

Anagrelide (Agrylin) 0.5 mg PO twice per day

Supportive therapy

ANAHYDRET: Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

Continued indefinitely

Dose and schedule modifications

ANAHYDRET: Anagrelide (Agrylin) increased until maintenance of the platelet count at normal (less than or equal to 450 x 10⁹/L) or close to normal levels (450 to 600 x 10⁹/L)
TEAM-ET 2.0: Anagrelide (Agrylin) titrated to goal platelet count of 150 to 400 x 10⁹/L

References

ANAHYDRET: Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01065038
TEAM-ET 2.0: Gisslinger H, Buxhofer-Ausch V, Hodisch J, Radinoff A, Karyagina E, Kyrcz-Krzemień S, Abdulkadyrov K, Gerbutavicius R, Melikyan A, Burgstaller S, Hus M, Kłoczko J, Yablokova V, Tzvetkov N, Całbecka M, Shneyder T, Warzocha K, Jurgutis M, Kaplanov K, Jilma B, Schoergenhofer C, Klade C. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial. Br J Haematol. 2019 May;185(4):691-700. Epub 2019 Mar 28. link to original article contains dosing details in manuscript link to PMC article PubMed EudraCT 2013‐003410‐41

Aspirin & Anagrelide

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Harrison et al. 2005 (UK MRC PT-1)	1997-2002	Phase 3 (E-switch-ooc)	Aspirin & Hydroxyurea	Seems to have inferior composite primary end point

Anticoagulation

Aspirin 75 mg (100 mg in Australia) PO once per day
Anagrelide (Agrylin) 0.5 mg PO twice per day

Continued indefinitely

Dose and schedule modifications

Anagrelide (Agrylin) doses were subsequently adjusted to maintain the platelet count at less than 400 x 10⁹/L

References

UK MRC PT-1: Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains dosing details in manuscript PubMed content property of HemOnc.org

Aspirin & Hydroxyurea

Regimen variant #1

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Harrison et al. 2005 (UK MRC PT-1)	1997-2002	Phase 3 (C)	Aspirin & Anagrelide	Seems to have superior composite primary end point

Chemotherapy

Hydroxyurea (Hydrea) 500 to 1000 mg PO once per day

Supportive therapy

Aspirin 75 mg (100 mg in Australia) PO once per day

Continued indefinitely

Dose and schedule modifications

Hydroxyurea (Hydrea) doses were subsequently adjusted to maintain the platelet count at less than 400 x 10⁹/L

Regimen variant #2

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Gisslinger et al. 2013 (ANAHYDRET)	2002-2006	Phase 3 (E-switch-ooc)	Anagrelide +/- Aspirin	Non-inferior composite primary endpoint

Chemotherapy

Hydroxyurea (Hydrea) 1500 mg PO once per day

Supportive therapy

Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

Continued indefinitely

Dose and schedule modifications

Hydroxyurea (Hydrea) increased until maintenance of the platelet count at normal (less than or equal to 450 x 10⁹/L) or close to normal levels (450 to 600 x 10⁹/L)

References

UK MRC PT-1: Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains dosing details in manuscript PubMed
ANAHYDRET: Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01065038

Hydroxyurea monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Cortelazzo et al. 1995	1990-1993	Phase 3 (E-esc)	Observation	Superior thrombotic episode rate

Chemotherapy

Hydroxyurea (Hydrea) 15 mg/kg/day PO

Continued indefinitely

Dose and schedule modifications

Hydroxyurea (Hydrea) doses were subsequently adjusted to maintain the platelet count at less than 600 x 10⁹/L without lowering the WBC count below 4 x 10⁹/L

References

Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains dosing details in manuscript PubMed

Peginterferon alfa-2a monotherapy

Regimen

Study	Dates of enrollment	Evidence
Quintás-Cardama et al. 2009 (MDACC DM03-0109)	NR	Phase 2

Note: This trial had several dose de-escalations due to toxicity and the dose here was the reported final starting dose.

Immunotherapy

Peginterferon alfa-2a (Pegasys) 90 mcg SC once on day 1

7-day cycles

References

MDACC DM03-0109: Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10;27(32):5418-24. Epub 2009 Oct 13. link to original article contains dosing details in abstract link to PMC article PubMed NCT00452023
1. Update: Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Aug 8;122(6):893-901. Epub 2013 Jun 19. link to original article link to PMC article PubMed
2. Update: Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr;4(4):e165-e175. Epub 2017 Mar 10. link to original article link to PMC article PubMed

Relapsed, refractory, or intolerant to initial therapy

Anagrelide monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Awaiting publication (SURPASS ET)	2020-NR	Phase 3 (C)	Ropeginterferon alfa-2b	Not reported

Anticoagulation

Anagrelide (Agrylin)

References

SURPASS ET: NCT04285086

Peginterferon alfa-2a monotherapy

Regimen

Study	Evidence
Verger et al. 2015	Observational

Note: Verger et al. 2015 do not specify a protocol but rather point to the European LeukemiaNet guidelines from 2011. All patients in this study had CALR mutations.

Immunotherapy

Peginterferon alfa-2a (Pegasys)

References

Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Dec 10;126(24):2585-91. Epub 2015 Oct 20. link to original article does not contain dosing details PubMed

Ruxolitinib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Verstovsek et al. 2017 (INCB 18424-256_ET)	2008-07 to 2009-04	Phase 2
Harrison et al. 2017 (MAJIC-ET)	2012-2015	Randomized Phase 2 (E-switch-ooc)	"Best available therapy"	Did not meet primary endpoint of CR rate

Note: recommended doses are starting doses.

Targeted therapy

Ruxolitinib (Jakafi) by the following laboratory-based criteria:
- Platelets between 100 to 200 x 10⁹/L: 20 mg PO twice per day
- Platelets greater than 200 x 10⁹/L: 25 mg PO twice per day

Supportive therapy

Aspirin 75 mg PO once per day was advised unless contraindicated (MAJIC-ET)

Continued indefinitely

Dose and schedule modifications

INCB 18424-256_ET: titrate to keep platelets less than 400 x 10⁹/L

References

MAJIC-ET: Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26;130(17):1889-1897. Epub 2017 Aug 9. link to original article link to PMC article contains dosing details in manuscript PubMed ISRCTN61925716
INCB 18424-256_ET: Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 Oct 12;130(15):1768-1771. Epub 2017 Aug 21. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00726232

Response criteria

ELN

2009: Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference PubMed

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-{| class="wikitable" style="text-align:center; width:50%;"
+{{#lst:Editorial board transclusions|mpn}}
-!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
-|-
-|style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|frameless|upright=0.3|center]]
-|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Vanderbilt University<br>Nashville, TN</big>
-|-
-|}
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 15: / Line 9: @@
 <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 |}
+''Are you looking for a regimen, but can't find it here? For placebo or observational studies in this condition, please visit [[Essential thrombocythemia - null regimens|this page]]. If you still can't find it, please let us know so we can add it!''<br>
+*''We have moved [[How I Treat]] articles to a dedicated page.''
 {{TOC limit|limit=3}}
 =Guidelines=
-*Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018 Jan 10;8(1):2. [https://www.nature.com/articles/s41408-017-0041-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29321520 PubMed]
+'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
+*Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018 Jan 10;8(1):2. [https://doi.org/10.1038/s41408-017-0041-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29321520/ PubMed]
 ==ELN==
-*'''2011:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979120/ Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet]
+*'''2011:''' Barbui et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979120/ Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet] [https://www.ncbi.nlm.nih.gov/pubmed/21205761 PubMed]
 ==ESMO==
-*'''2015:''' Vannucchi et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Philadelphia-Chromosome-Negative-Chronic-Myeloproliferative-Neoplasms Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
+*'''2015:''' Vannucchi et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Philadelphia-Chromosome-Negative-Chronic-Myeloproliferative-Neoplasms Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/26242182 PubMed]
-==[https://www.nccn.org/ NCCN]==
+==NCCN==
-*[https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf NCCN Guidelines - Myeloproliferative Neoplasms]
+*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477 NCCN Guidelines - Myeloproliferative Neoplasms].''
 =First-line therapy=
 ==Anagrelide monotherapy {{#subobject:fdd777|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:abf053|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 43: / Line 39: @@
 |style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
 |[[#Aspirin_.26_Hydroxyurea|Hydroxyurea +/- Aspirin]]
-|style="background-color:#eeee01"|Non-inferior composite endpoint
+|style="background-color:#eeee01"|Non-inferior composite primary endpoint
 |-
-|[https://doi.org/10.1111/bjh.15824 Gisslinger et al. 2019 (TEAM-ET 2.0)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6594023/ Gisslinger et al. 2019 (TEAM-ET 2.0)]
 |NR
 |style="background-color:#1a9851"|Phase 3 (C)
-|[[#A-PR_88|A-PR]]
+|[[#Anagrelide_monotherapy|Anagrelide]]; prolonged release
 |style="background-color:#eeee01"|Non-inferior mean platelet count
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Anticoagulation====
 *[[Anagrelide (Agrylin)]] 0.5 mg PO twice per day
 ====Supportive therapy====
 *ANAHYDRET: Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
 '''Continued indefinitely'''
+</div>
-====Dose modifications====
+<div class="toccolours" style="background-color:#fff2ae">
+====Dose and schedule modifications====
 *ANAHYDRET: [[Anagrelide (Agrylin)]] increased until maintenance of the platelet count at normal (less than or equal to 450 x 10<sup>9</sup>/L) or close to normal levels (450 to 600 x 10<sup>9</sup>/L)
 *TEAM-ET 2.0: [[Anagrelide (Agrylin)]] titrated to goal platelet count of 150 to 400 x 10<sup>9</sup>/L
+</div></div>
 ===References===
 <!-- Presented in parts in abstract form at the 50th annual meeting of the American Society of Hematology, December 7, 2008. -->
-# '''ANAHYDRET:''' Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. [http://www.bloodjournal.org/content/121/10/1720.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591796/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23315161 PubMed] NCT01065038
+# '''ANAHYDRET:''' Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. [https://doi.org/10.1182/blood-2012-07-443770 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591796/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23315161/ PubMed] [https://clinicaltrials.gov/study/NCT01065038 NCT01065038]
-# '''TEAM-ET 2.0:''' Gisslinger H, Buxhofer-Ausch V, Hodisch J, Radinoff A, Karyagina E, Kyrcz-Krzemień S, Abdulkadyrov K, Gerbutavicius R, Melikyan A, Burgstaller S, Hus M, Kłoczko J, Yablokova V, Tzvetkov N, Całbecka M, Shneyder T, Warzocha K, Jurgutis M, Kaplanov K, Jilma B, Schoergenhofer C, Klade C. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial. Br J Haematol. 2019 May;185(4):691-700. Epub 2019 Mar 28. [https://doi.org/10.1111/bjh.15824 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/30919941 PubMed]
+# '''TEAM-ET 2.0:''' Gisslinger H, Buxhofer-Ausch V, Hodisch J, Radinoff A, Karyagina E, Kyrcz-Krzemień S, Abdulkadyrov K, Gerbutavicius R, Melikyan A, Burgstaller S, Hus M, Kłoczko J, Yablokova V, Tzvetkov N, Całbecka M, Shneyder T, Warzocha K, Jurgutis M, Kaplanov K, Jilma B, Schoergenhofer C, Klade C. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial. Br J Haematol. 2019 May;185(4):691-700. Epub 2019 Mar 28. [https://doi.org/10.1111/bjh.15824 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6594023/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30919941/ PubMed] EudraCT 2013‐003410‐41
 ==Aspirin & Anagrelide {{#subobject:fdd555|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:bbeb21|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 85: / Line 82: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Anticoagulation====
 *[[Aspirin]] 75 mg (100 mg in Australia) PO once per day
 *[[Anagrelide (Agrylin)]] 0.5 mg PO twice per day
 '''Continued indefinitely'''
-====Dose modifications====
+</div>
+<div class="toccolours" style="background-color:#fff2ae">
+====Dose and schedule modifications====
 *[[Anagrelide (Agrylin)]] doses were subsequently adjusted to maintain the platelet count at less than 400 x 10<sup>9</sup>/L
+</div></div>
 ===References===
-# '''UK MRC PT-1:''' Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [https://doi.org/10.1056/NEJMoa043800 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16000354 PubMed] content property of [http://hemonc.org HemOnc.org]
+# '''UK MRC PT-1:''' Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [https://doi.org/10.1056/NEJMoa043800 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16000354/ PubMed] content property of [https://hemonc.org HemOnc.org]
 ==Aspirin & Hydroxyurea {{#subobject:762af3|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1 {{#subobject:d87ecc|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 113: / Line 111: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Hydroxyurea (Hydrea)]] 500 to 1000 mg PO once per day
 ====Supportive therapy====
 *[[Aspirin]] 75 mg (100 mg in Australia) PO once per day
 '''Continued indefinitely'''
-====Dose modifications====
+</div>
+<div class="toccolours" style="background-color:#fff2ae">
+====Dose and schedule modifications====
 *[[Hydroxyurea (Hydrea)]] doses were subsequently adjusted to maintain the platelet count at less than 400 x 10<sup>9</sup>/L
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2 {{#subobject:53255b|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 135: / Line 135: @@
 |style="background-color:#1a9851"|Phase 3 (E-switch-ooc)
 |[[#Aspirin_.26_Anagrelide|Anagrelide +/- Aspirin]]
-|style="background-color:#eeee01"|Non-inferior
+|style="background-color:#eeee01"|Non-inferior composite primary endpoint
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Hydroxyurea (Hydrea)]] 1500 mg PO once per day
 ====Supportive therapy====
 *Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
 '''Continued indefinitely'''
-====Dose modifications====
+</div>
+<div class="toccolours" style="background-color:#fff2ae">
+====Dose and schedule modifications====
 *[[Hydroxyurea (Hydrea)]] increased until maintenance of the platelet count at normal (less than or equal to 450 x 10<sup>9</sup>/L) or close to normal levels (450 to 600 x 10<sup>9</sup>/L)
+</div></div>
 ===References===
-# '''UK MRC PT-1:''' Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [https://doi.org/10.1056/NEJMoa043800 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16000354 PubMed]
+# '''UK MRC PT-1:''' Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [https://doi.org/10.1056/NEJMoa043800 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16000354/ PubMed]
 <!-- Presented in parts in abstract form at the 50th annual meeting of the American Society of Hematology, December 7, 2008. -->
-# '''ANAHYDRET:''' Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. [http://www.bloodjournal.org/content/121/10/1720.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591796/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23315161 PubMed] NCT01065038
+# '''ANAHYDRET:''' Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. [https://doi.org/10.1182/blood-2012-07-443770 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591796/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23315161/ PubMed] [https://clinicaltrials.gov/study/NCT01065038 NCT01065038]
 ==Hydroxyurea monotherapy {{#subobject:762af4|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:d87ecd|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 166: / Line 166: @@
 |1990-1993
 |style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[#Observation|Observation]]
+|[[Essential_thrombocythemia_-_null_regimens#Observation|Observation]]
 |style="background-color:#1a9850"|Superior thrombotic episode rate
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Hydroxyurea (Hydrea)]] 15 mg/kg/day PO
 '''Continued indefinitely'''
-====Dose modifications====
+</div>
+<div class="toccolours" style="background-color:#fff2ae">
+====Dose and schedule modifications====
 *[[Hydroxyurea (Hydrea)]] doses were subsequently adjusted to maintain the platelet count at less than 600 x 10<sup>9</sup>/L without lowering the WBC count below 4 x 10<sup>9</sup>/L
+</div></div>
 ===References===
-# Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. [https://doi.org/10.1056/NEJM199504273321704 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7700286 PubMed]
+# Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. [https://doi.org/10.1056/NEJM199504273321704 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7700286/ PubMed]
-==Observation==
-===Regimen===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1056/NEJM199504273321704 Cortelazzo et al. 1995]
-|1990-1993
-|style="background-color:#1a9851"|Phase 3 (C)
-|[[#Hydroxyurea_monotherapy|Hydroxyurea]]
-|style="background-color:#d73027"|Inferior thrombotic episode rate
-|-
-|}
-''No active antineoplastic treatment; used as a comparator arm.''
-===References===
-# Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. [https://doi.org/10.1056/NEJM199504273321704 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7700286 PubMed]
 ==Peginterferon alfa-2a monotherapy {{#subobject:83c030|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:e22ba1|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881362/ Quintás-Cardama et al. 2009 (MDACC DM03-0109)]
+|NR
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
-''This trial had several dose de-escalations due to toxicity and the dose here is the reported final starting dose.''
+''Note: This trial had several dose de-escalations due to toxicity and the dose here was the reported final starting dose.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Immunotherapy====
-*[[Peginterferon alfa-2a (Pegasys)]] 90 mcg SC once per day on days 1, 8, 15, 22
+*[[Peginterferon alfa-2a (Pegasys)]] 90 mcg SC once on day 1
+'''7-day cycles'''
-'''28-day cycles'''
+</div></div>
 ===References===
 <!-- no pre-pub disclosed -->
-# '''MDACC DM03-0109:''' Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10;27(32):5418-24. Epub 2009 Oct 13. [https://doi.org/10.1200/jco.2009.23.6075 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881362/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19826111 PubMed] NCT00452023
+# '''MDACC DM03-0109:''' Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10;27(32):5418-24. Epub 2009 Oct 13. [https://doi.org/10.1200/jco.2009.23.6075 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881362/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19826111/ PubMed] [https://clinicaltrials.gov/study/NCT00452023 NCT00452023]
-## '''Update:''' Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Aug 8;122(6):893-901. Epub 2013 Jun 19. [http://www.bloodjournal.org/content/122/6/893.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739035/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23782935 PubMed]
+## '''Update:''' Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013 Aug 8;122(6):893-901. Epub 2013 Jun 19. [https://doi.org/10.1182/blood-2012-07-442012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739035/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23782935/ PubMed]
-## '''Update:''' Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr;4(4):e165-e175. Epub 2017 Mar 10. [https://doi.org/10.1016/S2352-3026(17)30030-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421384/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28291640 PubMed]
+## '''Update:''' Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr;4(4):e165-e175. Epub 2017 Mar 10. [https://doi.org/10.1016/S2352-3026(17)30030-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421384/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28291640/ PubMed]
 =Relapsed, refractory, or intolerant to initial therapy=
 ==Anagrelide monotherapy {{#subobject:fhh777|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:abgb63|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|Awaiting publication (SURPASS ET)
+|[https://www.clinicaltrials.gov/study/NCT04285086 Awaiting publication (SURPASS ET)]
 |2020-NR
 |style="background-color:#1a9851"|Phase 3 (C)
-|[[#Ropeginterferon_alfa-2b_77|Ropeginterferon alfa-2b]]
+|[[#Ropeginterferon_alfa-2b_monotherapy_666|Ropeginterferon alfa-2b]]
 |style="background-color:#d3d3d3"|Not reported
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Anticoagulation====
 *[[Anagrelide (Agrylin)]]
+</div></div>
 ===References===
-#'''SURPASS ET:''' NCT04285086
+#'''SURPASS ET:''' [https://clinicaltrials.gov/study/NCT04285086 NCT04285086]
 ==Peginterferon alfa-2a monotherapy {{#subobject:9180b8|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:ee3318|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 259: / Line 238: @@
 !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
-|[http://www.bloodjournal.org/content/126/24/2585.long Verger et al. 2015]
+|[https://doi.org/10.1182/blood-2015-07-659060 Verger et al. 2015]
 |style="background-color:#91cf61"|Observational
 |-
 |}
-''Verger et al. 2015 do not specify a protocol but rather point to the European LeukemiaNet guidelines from 2011. All patients in this study had CALR mutations.''
+''Note: Verger et al. 2015 do not specify a protocol but rather point to the European LeukemiaNet guidelines from 2011. All patients in this study had CALR mutations.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Immunotherapy====
 *[[Peginterferon alfa-2a (Pegasys)]]
+</div></div>
 ===References===
-# Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Dec 10;126(24):2585-91. Epub 2015 Oct 20. [http://www.bloodjournal.org/content/126/24/2585.long link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/26486786 PubMed]
+# Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Dec 10;126(24):2585-91. Epub 2015 Oct 20. [https://doi.org/10.1182/blood-2015-07-659060 link to original article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/26486786/ PubMed]
 ==Ruxolitinib monotherapy {{#subobject:7f01ff|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:fac447|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[http://www.bloodjournal.org/content/130/15/1768.long Verstovsek et al. 2017 (INCB 18424-256)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5639482/ Verstovsek et al. 2017 (INCB 18424-256<sub>ET</sub>)]
-|2008-2009
+|2008-07 to 2009-04
 |style="background-color:#91cf61"|Phase 2
 |style="background-color:#d3d3d3"|
 |style="background-color:#d3d3d3"|
 |-
-|[http://www.bloodjournal.org/content/130/17/1889.long Harrison et al. 2017 (MAJIC-ET)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6410531/ Harrison et al. 2017 (MAJIC-ET)]
 |2012-2015
 |style="background-color:#1a9851"|Randomized Phase 2 (E-switch-ooc)
@@ Line 293: / Line 272: @@
 |-
 |}
-''Note: Harrison et al. 2017 does not specify a starting dose.''
+''Note: recommended doses are starting doses.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
-*[[Ruxolitinib (Jakafi)]] as follows:
+*[[Ruxolitinib (Jakafi)]] by the following laboratory-based criteria:
-**Starting dose: 25 mg PO twice per day
+**Platelets between 100 to 200 x 10<sup>9</sup>/L: 20 mg PO twice per day
-**Titrate to keep platelets less than 400 x 10<sup>9</sup>/L
+**Platelets greater than 200 x 10<sup>9</sup>/L: 25 mg PO twice per day
+====Supportive therapy====
+*[[Aspirin]] 75 mg PO once per day was advised unless contraindicated (MAJIC-ET)
 '''Continued indefinitely'''
+</div>
+<div class="toccolours" style="background-color:#fff2ae">
+====Dose and schedule modifications====
+*INCB 18424-256<sub>ET</sub>: titrate to keep platelets less than 400 x 10<sup>9</sup>/L
+</div></div>
 ===References===
-# '''MAJIC-ET:''' Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26;130(17):1889-1897. Epub 2017 Aug 9. [http://www.bloodjournal.org/content/130/17/1889.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/29074595 PubMed] ISRCTN61925716
+# '''MAJIC-ET:''' Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26;130(17):1889-1897. Epub 2017 Aug 9. [https://doi.org/10.1182/blood-2017-05-785790 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6410531/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29074595/ PubMed] ISRCTN61925716
-# '''INCB 18424-256:''' Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 Oct 12;130(15):1768-1771. Epub 2017 Aug 21. [http://www.bloodjournal.org/content/130/15/1768.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28827411 PubMed]
+# '''INCB 18424-256<sub>ET</sub>:''' Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 Oct 12;130(15):1768-1771. Epub 2017 Aug 21. [https://doi.org/10.1182/blood-2017-02-765032 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5639482/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28827411/ PubMed] [https://clinicaltrials.gov/study/NCT00726232 NCT00726232]
 =Response criteria=
 ==ELN==
-*'''2009:''' [http://www.bloodjournal.org/content/113/20/4829.long Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference]
+*'''2009:''' [https://doi.org/10.1182/blood-2008-09-176818 Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference] [https://pubmed.ncbi.nlm.nih.gov/19278953/ PubMed]
 [[Category:Essential thrombocythemia regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Myeloproliferative neoplasms]]

Difference between revisions of "Essential thrombocythemia"

Latest revision as of 22:55, 27 June 2024

Guidelines

ELN

ESMO

NCCN

First-line therapy

Anagrelide monotherapy

Regimen

Anticoagulation

Supportive therapy

Dose and schedule modifications

References

Aspirin & Anagrelide

Regimen

Anticoagulation

Dose and schedule modifications

References

Aspirin & Hydroxyurea

Regimen variant #1

Chemotherapy

Supportive therapy

Dose and schedule modifications

Regimen variant #2

Chemotherapy

Supportive therapy

Dose and schedule modifications

References

Hydroxyurea monotherapy

Regimen

Chemotherapy

Dose and schedule modifications

References

Peginterferon alfa-2a monotherapy

Regimen

Immunotherapy

References

Relapsed, refractory, or intolerant to initial therapy

Anagrelide monotherapy

Regimen

Anticoagulation

References

Peginterferon alfa-2a monotherapy

Regimen

Immunotherapy

References

Ruxolitinib monotherapy

Regimen

Targeted therapy

Supportive therapy

Dose and schedule modifications

References

Response criteria

ELN

Navigation menu

Search